ERBB2 and neoplasm: Interestingly, case PA1 displayed an equivocal HER2 immunohistochemical pattern of expression (2+ score), showing weak–moderate basolateral membrane immunoreactivity in 10% of tumor cells; FISH analysis revealed a heterogeneous pattern for HER2 amplification.